For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-cancer-immunotherapy-market-and-clinical-trials-outlook-2022.php
Table of Contents
1. Immunotherapy: Mending Cancer Regimens
1.1 Preface to Cancer Immunotherapy
1.2 Evolution of Cancer Immunotherapy
2. Categorization of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
3. Fundamentals of Cancer Vaccines
3.1 Prologue of Cancer Vaccines
3.2 Cancer Vaccines in Immunotherapy
3.3 Commercial Aspects of Cancer Vaccines
4. New Era of Monoclonal Antibodies
4.1 Rudiments of Monoclonal Antibodies
4.2 Advents of Monoclonal Antibodies
4.3 Commercial Aspects of Monoclonal Antibodies
5. Trails of T-Cell Therapies
5.1 Adoptive Cell Transfer Technology
5.2 Strategies of Adoptive Cell Transfer
5.3 Commercial Aspects of Adoptive Cell Therapy
6. Aspects of Immune Checkpoint Inhibitors
6.1 Prelude to Immune Checkpoint Inhibitors
6.2 Implications of Immunecheck Point Inhibitors
6.3 Commercial Aspects of Immune Checkpoint Inhibitors
7. Immunomodulators in Cancer Immunotherapy
7.1 Perspective of Immunomodulators
7.2 Clinical Aspects of Immunomodulators
7.3 Commercial Aspects of Immunomodulators
8. Oncolytic Viral Immunotherapy
8.1 Concept to Oncolytic Viruses
8.2 Potential Approaches of Oncolytic Viruses
8.3 Commercial Aspects of Oncolytic Viruses
9. Cytokines in Cancer Immunotherapy
9.1 Fundamentals of Cytokines
9.2 Classification of Cytokines
9.3 Commercial Aspects of Cytokines
10. Interferons in Immunotherapy
10.1 Potentials of Interferons
10.2 Classification of Interferons
10.3 Clinical Applications of Interferons
11. Interleukins in Immunotherapy
11.1 Potentials of Interleukins
11.2 Clinical Applications of Interleukins
12. GM-CSF in Immunotherapy
12.1 Potentials of GM-CSF
12.2 Clinical Applications of GM-CSF
13. Global Economic Evaluations
13.1 Economic Aspects of Cancer Immunotherapy
13.2 Cancer Immunotherapy Cost by Product
14. Market Aspects of Cancer Immunotherapy
14.1 Current Market Trends
14.2 Cancer Immunotherapy Pipeline Overview
15. Global Cancer Immunotherapy Market Dynamics
15.1 Favorable Market Parameters
15.2 Commercialization Challenges
16. Marketed Cancer Cell Therapies Drugs
16.1 Sipuleucel-T (Provengeandreg;)
16.2 T-Lymphocyte Cell Therapy(Immuncell-LCandreg;)
17. Marketed Cancer Cytokines Drugs
17.1 Aldesleukin (Proleukinandreg;)
17.2 Denileukin Diftitox (ONTAKandreg;)
17.3 Interferon Alpha (Multiferonandreg;)
17.4 Interferon Alpha-2a (Roferon-Aandreg;)
17.5 Interferon Alpha-2a (Veldonaandreg;)
17.6 Interferon Alpha-2a Biosimilar(Inferonandtrade;/Inmutagandtrade;)
17.7 Interferon Alpha-2b(Intronandreg; A)
17.8 Interferon Alpha-2b Biosimilar(Bioferonandtrade;)
17.9 Interferon Alpha-2b Biosimilar (Intalfaandreg;)
17.10 Interferon Alpha-2b Biosimilar
17.11 Interferon-Alpha-n3 (Alferon Nandreg;)
17.12 Interferon-Beta-1b (Feronandreg;)
17.13 Interferon-Gamma (Ogammaandreg;)
17.14 Interleukin-2 Biosimilar (Ilcass)
17.15 Teceleukin (Imunaceandtrade;)
18. Marketed Cancer Vaccines
18.1 Bladder Cancer Vaccine (PACISandreg;)
18.2 Bladder Cancer Vaccine
18.3 BV NSCLC 001
18.4 Dendritic Cell Vaccine (CreaVax-HCCandreg;, CreaVax-PCandreg; and CreaVax-RCCandreg;)
18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasilandreg;/Silgardandreg;)
18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarixandreg;)
18.7 Melanoma Vaccine (MVaxandreg;)
18.8 Melanoma Vaccine (Melacineandreg;)
18.9 Racotumomab (Vaxiraandreg;)
18.10 Sipuleucel-T (Provengeandreg;)
18.11 Tertomotide (LucaVax)
18.12 Vitespen (Oncophageandreg;)
19. Marketed Cancer Monoclonal Antibodies
19.1 Bevacizumab
19.2 Trastuzumab Emtansine
19.3 Trastuzumab Subcutaneous
19.4 Brentuximab Vedotin
19.5 Catumaxomab
19.6 Ipilimumab
19.7 Nivolumab
19.8 Pembrolizumab
19.9 Pertuzumab
19.10 Rituximab
19.11 Trastuzumab
20. Global Cancer Immunotherapy Market Future Prospects
21. Competitive Landscape
21.1 Abbvie
21.2 Advaxis
21.3 Altor BioScience
21.4 Amgen
21.5 Biogen Idec
21.6 Biogenomics
21.7 Celldex Therapeutics
21.8 Dendreon Corporation
21.9 Eli Lilly
21.10 Expression Genetics
21.11 Galena Biopharma
21.12 Genmab
21.13 Gilead Sciences
21.14 GlaxoSmithKline
21.15 ImmunoCellular Therapeutics
21.16 ImmunoGen
21.17 Inovio Pharmaceuticals
21.18 IRX Therapeutics
21.19 Merck
21.20 NeoStem Oncology
21.21 NewLink Genetics
21.22 Northwest Biotherapeutics
21.23 Novartis
21.24 Peregrine Pharmaceuticals
21.25 Pfizer
21.26 Philogen
21.27 Regulon
21.28 Roche
21.29 Seattle Genetics
21.30 ZymoGenetics
Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Categorization and Function of Cancer Vaccines
Figure 3-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 3-3: Global Cancer Vaccines Market (US$ Billion), 2016-2022
Figure 4-1: Process of Manufacturing of Monoclonal Antibody
Figure 4-2: Principles of Monoclonal Antibodies
Figure 4-3: Evolution of Monoclonal Antibody over Generations
Figure 4-4: Classification of Monoclonal Antibodies
Figure 4-5: Representation of Mechanism of Alemtuzumab
Figure 4-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 4-7: Representation of Mechanism of Blinatumomab
Figure 4-8: Global Market for Cancer Monoclonal Antibodies (US$ Billion), 2016-2022
Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 5-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 5-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 5-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 5-5: Mechanism of CAR Modified T-Cells
Figure 5-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 5-7: Global Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2016-2022
Figure 6-1: Benefits of Immune Checkpoint Inhibitors
Figure 6-2: Implication of Adaptive Immune Resistance Mechanism
Figure 6-3: Mechanism of Ipilimumab
Figure 6-4: Layout of Mechanism of Nivolumab
Figure 6-5: Mechanism of Pembrolizumab
Figure 6-6: Global – Immune Check Point Inhibitors Market (US$ Billion), 2016-2022
Figure 7-1: Functions of Immunomodulators
Figure 7-2: Benefits of Immunomodulators
Figure 7-3: Layout of the Challenges of Immunomodulators
Figure 7-4: Properties of Thalidomide
Figure 7-5: Mechanism of Lenalidomide In Vivo
Figure 7-6: Mechanism of Lenalidomide in Vitro
Figure 7-7: Mechanism of Pomalidomide
Figure 7-8: The Global Market for Immunomodulators for All Indications (US$ Billion), 2016-2022
Figure 8-1: Demonstration of Categorization of Oncolytic Viruses
Figure 8-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 8-3: The Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2016-2022
Figure 9-1: Layout of Functions Performed by Cytokine
Figure 9-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 9-3: Classification of Cytokine Receptor Family
Figure 9-4: Percentage Share of the Cancer Immunotherapies by the Technology
Figure 10-1: Layout of Functions of Interferon
Figure 10-2: Classification of Interferons on the Basis of Types of Genes
Figure 10-3: General Mechanism of Interferons
Figure 10-4: Mechanism of Interferon Alfa-n3
Figure 10-5: Aspects of Peginterferon Alfa-2a
Figure 10-6: Applications of Interferon Beta 1a
Figure 10-7: Potentials of Interferon Alfa-2b
Figure 11-1: Functions of Interleukin
Figure 11-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 11-3: Clinical Potentials of Proleukin
Figure 11-4: Clinical Potentials of Denileukin Diftitox
Figure 12-1: Potential Applications of GM-CSF
Figure 12-2: Mechanism of Sargramostim
Figure 13-1: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 13-2: Comparative Analysis of Available Cancer Treatments
Figure 13-3: Major Approved Immunotherapeutic Drugs
Figure 13-4: Annual per Patient Drug Expenditure of Immunotherapy
Figure 14-1: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 14-2: Global – Cancer Vaccine Clinical Pipeline by Phase (%), 2017 – 2022
Figure 14-3: Global – Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-4: Global – Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-5: Global – Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-6: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-7: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-8: Global – Cancer Cell Therapies Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-9: Global – Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2017 -2022
Figure 14-10: Global – Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022
Figure 14-11: Global – Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 – 2022
Figure 14-12: Global – Cancer Immunomodulators Clinical Pipeline by Phase (%), 2017 – 2022
Figure 14-13: Global – Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2017 – 2022
Figure 15-1: Favorable Cancer Immunotherapy Market Parameters
Figure 15-2: Cancer Immunotherapy Commercialization Challenges
Figure 21-1: Advaxis Clinical Pipeline
Figure 21-2: Celldex Therapeutics Clinical Pipeline
Figure 21-3: Expression Genetics Clinical Pipeline
Figure 21-4: Galena Biopharma Clinical Pipeline
Figure 21-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 21-6: ImmunoGen Clinical Pipeline
Figure 21-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 21-8: NewLink Genetics Corporation Clinical Pipeline
Figure 21-9: Northwest Biotherapeutics Clinical Pipeline
Figure 21-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 21-11: Philogen Clinical Pipeline
Figure 21-12: Seattle Genetics Clinical Pipeline
Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 6-1: Illustration of Some Important Checkpoint Inhibitors
Table 9-1: Few Important Immunocytokines under Clinical Development
Table 9-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs